Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979362 · ClinicalTrials.gov registry record · Phase 2
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
A Phase 2 study of Heart Failure, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06979362: Recruiting Phase 2 study of Heart Failure, sponsored by Novo Nordisk A/S.
NCT06979362 is a Phase 2 study of Heart Failure that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 200 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06979362, a Phase 2 study of Heart Failure, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Primary Outcome
Measured as ratio to baseline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CDR132L
Study Locations (20)
California
- Valley Clinical Trials - Covina
- UCSD NAFLD Research Center - La Jolla
- Valley Clinical Trials - Northridge
- University of California, San Francisco - San Francisco
- University of California San Francisco UCSF - San Francisco
- Harbor-UCLA Medical Center - Torrance
Florida
- Inpatient Research Clinic LLC - Miami Lakes
- AdventHealth Orlando - Orlando
- Guardian Research Org LLC - Winter Park
Arizona
- TMC Hlthcr Clin Res Office - Tucson
- Pima Heart and Vascular - Tucson
Alabama
- Univ of Alabama Birmingham - Birmingham
Colorado
- CPC Clinical Research & Community Health - Aurora
Kentucky
- UofL Health Care Outpatient - Louisville
Michigan
- Henry Ford Hospital_Detroit - Detroit
Minnesota
- University of Minnesota_Minneapolis_1 - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2028-01-23 |
| Phase | Phase 2 |
What NCT06979362 shows while recruiting
NCT06979362 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06979362 names 20 study sites across 12 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06979362 about?
NCT06979362 is a clinical study titled "A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy". This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chan...
What is the current status of trial NCT06979362?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-06-27. Estimated completion is 2028-01-23.
What conditions does trial NCT06979362 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT06979362?
The interventions under investigation include: Placebo (DRUG), CDR132L (DRUG).
Who is sponsoring clinical trial NCT06979362?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979362 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06979362's enrollment target sits among peer trials
200 165th of 397 higher than 229 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI